These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30872949)

  • 1. Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.
    Hao L; Shi Y; Thomas S; Vezina CM; Bajpai S; Ashok A; Bieberich CJ; Ricke WA; Li L
    Int J Mass Spectrom; 2018 Nov; 434():185-192. PubMed ID: 30872949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Metabolomic and Proteomic Analyses in a Mouse Model of Prostatic Inflammation.
    Wei P; Hao L; Ma F; Yu Q; Buchberger AR; Lee S; Bushman W; Li L
    Urine (Amst); 2019 Jun; 1():17-23. PubMed ID: 33870183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.
    Hao L; Greer T; Page D; Shi Y; Vezina CM; Macoska JA; Marker PC; Bjorling DE; Bushman W; Ricke WA; Li L
    Sci Rep; 2016 Aug; 6():30869. PubMed ID: 27502322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
    Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
    Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urine metabolomics analysis based on ultra performance liquid chromatography-high resolution mass spectrometry combined with osmolality calibration sample concentration variability].
    He Z; Lin H; Gui J; Zhu W; He J; Wang H; Feng L
    Se Pu; 2021 Apr; 39(4):391-398. PubMed ID: 34227759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction.
    Pattabiraman G; Bell-Cohn AJ; Murphy SF; Mazur DJ; Schaeffer AJ; Thumbikat P
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F466-F479. PubMed ID: 34423679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between interleukin-6 and lower urinary tract symptoms of benign prostatic hyperplasia.
    Zhang Q; Jiang K; Huo RC; Zhang JQ; Yang ZG
    Rev Int Androl; 2023; 21(2):100334. PubMed ID: 36266235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostatic fibrosis: Progress in studies].
    Zhang JC; Zhao F; Duan Y
    Zhonghua Nan Ke Xue; 2020 Jan; 26(1):83-87. PubMed ID: 33345483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.
    Puhka M; Takatalo M; Nordberg ME; Valkonen S; Nandania J; Aatonen M; Yliperttula M; Laitinen S; Velagapudi V; Mirtti T; Kallioniemi O; Rannikko A; Siljander PR; Af Hällström TM
    Theranostics; 2017; 7(16):3824-3841. PubMed ID: 29109780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary Amine Metabolomics Characterization with Custom 12-Plex Isobaric DiLeu Labeling.
    Wei P; Hao L; Thomas S; Buchberger AR; Steinke L; Marker PC; Ricke WA; Li L
    J Am Soc Mass Spectrom; 2020 Sep; 31(9):1854-1860. PubMed ID: 32678615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of prostate inflammation and fibrosis in lower urinary tract symptoms.
    Bushman WA; Jerde TJ
    Am J Physiol Renal Physiol; 2016 Oct; 311(4):F817-F821. PubMed ID: 27440781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis.
    Nandalur KR; Walker D; Ye H; Al-Katib S; Seifman B; Gangwish D; Dhaliwal A; Connor E; Dobies K; Sesoko C; Dejoie W; Zwaans B; Nandalur S; Nguyen J; Hafron J
    Prostate; 2023 Feb; 83(3):259-267. PubMed ID: 36344473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine for the management of benign prostatic hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Olumi AF
    J Urol; 2014 Jul; 192(1):16-23. PubMed ID: 24582540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of statistical techniques to normalize mass spectrometry-based urinary metabolomics data.
    Cook T; Ma Y; Gamagedara S
    J Pharm Biomed Anal; 2020 Jan; 177():112854. PubMed ID: 31518861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-Specific Deletion of Cdh1 Induces Murine Prostatic Inflammation and Bladder Overactivity.
    Pascal LE; Mizoguchi S; Chen W; Rigatti LH; Igarashi T; Dhir R; Tyagi P; Wu Z; Yang Z; de Groat WC; DeFranco DB; Yoshimura N; Wang Z
    Endocrinology; 2021 Jan; 162(1):. PubMed ID: 33211830
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.